Interleukin (IL)-1 Blockade in Acute Heart Failure (Anakinra ADHF)
Status:
Completed
Trial end date:
2015-05-01
Target enrollment:
Participant gender:
Summary
Anakinra ADHF is a double-blind randomized clinical trial of anakinra, recombinant human
interleukin-1 receptor blocker, or placebo in patients with acute decompensated heart failure
with the aim to quench the acute inflammatory response, as measured by the
area-under-the-curve for C reactive protein over 14 days.